Encephalopathy in Cirrhosis: Prevention and Management

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2022 Jun 9

PMID 35677508

Authors

Amrish Sahney

Manav Wadhawan

Affiliations

Soon will be listed here.

Abstract

Hepatic encephalopathy (HE) is a major neuropsychiatric complication of cirrhosis. The clinical manifestations of HE ranges from mild confusion, disorientation to altered behaviour and coma in advanced stages. HE is an important cause of recurrent admissions in liver cirrhosis patients. HE is the most common cause of altered mentation in a patient of liver cirrhosis. Lactulose and rifaximin are approved treatment options for the treatment of HE. In patients who have localised neurological signs or are not improving with lactulose and rifaximin should be investigated for other causes of altered sensorium.

Citing Articles

The Role of Vitamin D Deficiency in Hepatic Encephalopathy: A Review of Pathophysiology, Clinical Outcomes, and Therapeutic Potential.

Johnson C, Stevens C, Bennett M, Litch A, Rodrigue E, Quintanilla M Nutrients. 2024; 16(23).

PMID: 39683402 PMC: 11643663. DOI: 10.3390/nu16234007.

Management of Portal Hypertension.

Kulkarni A, Rabiee A, Mohanty A J Clin Exp Hepatol. 2022; 12(4):1184-1199.

PMID: 35814519 PMC: 9257868. DOI: 10.1016/j.jceh.2022.03.002.

References

Leise M, Poterucha J, Kamath P, Kim W . Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014; 89(2):241-53. PMC: 4128786. DOI: 10.1016/j.mayocp.2013.11.009. View

Mittal V, Sharma B, Sharma P, Sarin S . A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011; 23(8):725-32. DOI: 10.1097/MEG.0b013e32834696f5. View

Rahimi R, Elliott A, Rockey D . Altered mental status in cirrhosis: etiologies and outcomes. J Investig Med. 2013; 61(4):695-700. DOI: 10.2310/JIM.0b013e318289e254. View

Lopez-Franco O, Morin J, Cortes-Sol A, Molina-Jimenez T, Del Moral D, Flores-Munoz M . Cognitive Impairment After Resolution of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis. Front Neurosci. 2021; 15:579263. PMC: 8006450. DOI: 10.3389/fnins.2021.579263. View

Goral V, Atayan Y, Kaplan A . The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor α?. Hepatogastroenterology. 2011; 58(107-108):943-8. View

Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G . Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013; 57(6):2448-57. DOI: 10.1002/hep.26314. View

Dhiman R, Saraswat V, Sharma B, Sarin S, Chawla Y, Butterworth R . Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010; 25(6):1029-41. DOI: 10.1111/j.1440-1746.2010.06318.x. View

Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F . Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004; 41(1):38-43. DOI: 10.1016/j.jhep.2004.03.023. View

Mallet M, Weiss N, Thabut D, Rudler M . Why and when to measure ammonemia in cirrhosis?. Clin Res Hepatol Gastroenterol. 2018; 42(6):505-511. DOI: 10.1016/j.clinre.2018.01.004. View

10.

Gluud L, Dam G, Borre M, Les I, Cordoba J, Marchesini G . Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013; 143(8):1263-8. DOI: 10.3945/jn.113.174375. View

11.

Saunders J, Walters J, Davies A, Paton A . A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed). 1981; 282(6260):263-6. PMC: 1504019. DOI: 10.1136/bmj.282.6260.263. View

12.

Gluud L, Dam G, Les I, Marchesini G, Borre M, Aagaard N . Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017; 5:CD001939. PMC: 6481897. DOI: 10.1002/14651858.CD001939.pub4. View

13.

Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S . Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol. 2016; 15(6):934-936. DOI: 10.1016/j.cgh.2016.10.028. View

14.

Sharma B, Sharma P, Lunia M, Srivastava S, Goyal R, Sarin S . A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013; 108(9):1458-63. DOI: 10.1038/ajg.2013.219. View

15.

Rahimi R, Safadi R, Thabut D, Bhamidimarri K, Pyrsopoulos N, Potthoff A . Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clin Gastroenterol Hepatol. 2020; 19(12):2626-2635.e7. DOI: 10.1016/j.cgh.2020.10.019. View

16.

Amodio P, Del Piccolo F, Petteno E, Mapelli D, Angeli P, Iemmolo R . Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001; 35(1):37-45. DOI: 10.1016/s0168-8278(01)00129-5. View

17.

Sharma P, Sharma B, Agrawal A, Sarin S . Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012; 27(8):1329-35. DOI: 10.1111/j.1440-1746.2012.07186.x. View

18.

Kircheis G, Luth S . Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. Drugs. 2019; 79(Suppl 1):23-29. PMC: 6416235. DOI: 10.1007/s40265-018-1023-2. View

19.

Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V . Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2012; 28(2):281-4. DOI: 10.1007/s11011-012-9365-z. View

20.

Dadsetan S, Sorensen M, Bak L, Vilstrup H, Ott P, Schousboe A . Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia. Biochem Pharmacol. 2012; 85(1):115-23. DOI: 10.1016/j.bcp.2012.10.015. View